Literature DB >> 25311349

MSLT-I-response of clinical trial investigators.

Mark B Faries1, Alistair J Cochran2, John F Thompson3.   

Abstract

Mesh：

Year:  2014        PMID： 25311349     DOI： 10.1038/nrclinonc.2014.65-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-04-08       Impact factor: 66.675

2.  Melanoma: MSLT-1--putting sentinel lymph node biopsy into context.

Authors:  Vernon K Sondak; Jonathan S Zager
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

3.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Authors:  Alexander M M Eggermont; Stefan Suciu; Alessandro Testori; Wim H Kruit; Jeremy Marsden; Cornelis J Punt; Mario Santinami; François Salès; Dirk Schadendorf; Poulam Patel; Reinhard Dummer; Caroline Robert; Ulrich Keilholz; Antoine Yver; Alan Spatz
Journal:  Eur J Cancer       Date:  2011-11-05       Impact factor: 9.162

4.  The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Authors:  Mark B Faries; John F Thompson; Alistair Cochran; Robert Elashoff; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-Jing Wang; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2010-07-08       Impact factor: 5.344

Review 5.  Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson
Journal:  J Surg Oncol       Date:  2011-09       Impact factor: 3.454

Review 6.  Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials.

Authors:  Marko B Lens; Martin Dawes; Tim Goodacre; Julia A Newton-Bishop
Journal:  Arch Surg       Date:  2002-04

7.  A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial.

Authors:  Lily L Altstein; Gang Li; Robert M Elashoff
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

8.  Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

Authors:  L Altstein; G Li
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

9.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

10.  Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma?

Authors:  James C Yang; Richard M Sherry; Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675
  10 in total
  2 in total

1.  MSLT-I-response of clinical trial investigators.

Authors:  James C Yang; Richard M Sherry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

2.  SLNB in melanoma-DFS a true and cost-effective benefit?

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.